Avigen Inc

Premium Company Profile

Publication Date	April 2008
Publisher	Datamonitor
Product Type	Report
Pages	39
ISBN Number	not applicable
Product Code	DAT11486

Price

£265.00
approximately: $521 | €337

PDF

PRINT £315 ($619 | €400)

Order above formats by FAX

Summary

Introduction

Avigen is a development stage biopharmaceutical company focusing on small molecule therapeutics and biologics to treat neurological and neuromuscular disorders. The company's current pipeline products primarily address spasticity and neuromuscular spasm and neuropathic pain.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Avigen's development programs include AV650 in Phase II trials for spasticity and neuromuscular spasm; AV411 in Phase I trials and AV333 in preclinical for neuropathic pain. Further, in collaboration with University of Colorado Avigen explores the use of AV411 for opioid withdrawal. The company's revenues increased at a CAGR of 16% during 2002-2006 from $0.057 million to $0.103 million. The increase in revenues was primarily due to the deferred revenues from Bayer in connection with the development of Coagulin-B for the treatment of hemophilia-B. In addition, Avigen received license fee and royalty payments on adeno-associated virus (AAV) technology; and grants from National Institutes of Health (NIH) for exploring the use of AV411 for neuropathic pain, in collaboration with University of Colorado.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization .

Content

Overview
Catalyst
Summary
- Company Structure
- Company Overview and Key Facts
- Business Description
- History
- Company Financials
- Stock Market Performance
- P&l
- Balance Sheet
- Cash Flow
- Products & Services
- Pipeline Products
- Competitors and Strategic Business Relationships
- Key Competitors
- Key Suppliers
- Key Clients
- Shareholding Structure
- Strategy
- Company View
- Corporate Strategy
- SWOT Analysis
- Overview
- Strengths
- Weaknesses
- Opportunities
- Threats
- Value Chain Analysis
- Overview
- Discovery and Product Development
- Key Employees
- List of Employees
- Key Employee Biographies
- Financial and Operational Overview
- Financial and Operational Overview
Appendix
- Ask The Analyst
- Datamonitor Consulting
- Disclaimer
Table of Figures
- Figure 1: Avigen - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Table of Tables
- Table 1: Avigen - Key Facts
- Table 2: Avigen - Year-End Share Price and Market Capitalization, 2002-2006 ($)
- Table 3: Avigen - Key Events Impacting Share Price Performance
- Table 4: Avigen - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Table 5: Avigen - Operating Cost Ratio Analysis, 2002-2006 (% of Total Revenues)
- Table 6: Avigen - Balance Sheet
- Table 7: Avigen - Cash Flow
- Table 8: Avigen - in-House Pipeline Products
- Table 9: Avigen - Key Competitors
- Table 10: Avigen - Key Suppliers
- Table 11: Avigen - Key Clients
- Table 12: Avigen - Key Shareholders
- Table 13: Avigen - SWOT Analysis Summary
- Table 14: Avigen - Value Chain Analysis
- Table 15: Avigen - Key Employees
- Table 16: Avigen- Financial and Operational Overview